• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Apollomics Inc. - Warrant (NQ: APLMW )

    0.0130 -0.0026 (-16.67%)
    Streaming Delayed Price Updated: 9:30 AM EDT, Jun 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 230
    Open 0.0130
    Bid (Size) 0.0100 (2)
    Ask (Size) 0.0156 (149)
    Prev. Close 0.0156
    Today's Range 0.0130 - 0.0130
    52wk Range 0.0080 - 0.0989
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    Data from Phase 2 and 2/3 trials demonstrate continued efficacy and safety of vebreltinib for treating different tumor types carrying MET-driver alterations 
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Presentation at the 2024 BIO International Convention
    From Apollomics Inc.
    Via GlobeNewswire

    Performance

    YTD
    -60.00%
    -60.00%
    1 Month
    -47.79%
    -47.79%
    3 Month
    -49.81%
    -49.81%
    6 Month
    -52.73%
    -52.73%
    1 Year
    -83.95%
    -83.95%

    More News

    Read More
    Apollomics Announces Private Placement Financing and Addition to Board of Directors
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics to Present at the 2024 Biotech Showcase
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium
    From Apollomics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.